Futura Medical plc announced that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health ("Cooper"), for the rights to commercialise Eroxon, the Company's topical, gel-based Erectile Dysfunction ("ED") treatment, throughout the European Economic Area, United Kingdom and Switzerland. The extension builds on an initial agreement signed in May 2022 for the exclusive rights to commercialize Eroxon in these territories for an initial five-year period. The terms of the agreement are otherwise unchanged with Futura remaining the Legal Manufacturer1 and responsible for the supply of Eroxon through its third-party contract manufacturers.

Futura looks forward to continuing to grow its relationship with Cooper. Eroxon has been approved as the first pan-European topical treatment for ED available without prescription. Initial launches commenced in March 2023 in the UK and Belgium, with further launches across Europe during 2024, including the key markets of Italy, Spain, France and Germany.

Legal manufacturer means the organisation responsible for the design, manufacture, packaging and labelling of a device before it is placed on the market under that organisation's own name, regardless of whether these operations are carried out by that organisation or on its behalf by a third party contract manufacturer.